Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.

Pharmacogenomics - 1 Jan 2025

Counts Christopher, Ali Nisha, Ali Syed, Muhammad Kafilah A, Diop Fatoumata B, Sims Keith, Ajoku Amarachukwu, Santos Cynthia

Abstract excerpt

Naltrexone is an opioid receptor antagonist used to treat alcohol use disorder; however, like other commonly used addiction treatment options, it demonstrates inconsistency in treatment response. Pharmacogenomics may be used to individualize addiction treatment and identify patients who would be better candidates for this drug. Recently, the Clinical Pharmacogenomics Implementation Consortium (CPIC) provided...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Dehydrogenase
Share to Alcoholism

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aldehyde Dehydrogenase

Share to Naltrexone

Share to Narcotic Antagonists

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Receptors, Opioid, mu

Source

Open in PubMed Open full text

Identifiers

PMID: 41553151
DOI: 10.1080/14622416.2026.2613634
PMCID: PMC12915813

Genes

OPRM1
ADH1B
ALDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.PMID 41553151Read ↗

Opioid pharmacogenetics of alcohol addiction.Semantic proximity Read ↗

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.Semantic proximity Read ↗

Pharmacogenetic treatments for drug addiction: alcohol and opiates.Semantic proximity Read ↗

Pharmacogenetics of alcohol, nicotine and drug addiction treatments.Semantic proximity Read ↗

Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder.Semantic proximity Read ↗

Pharmacogenetically driven treatments for alcoholism: are we there yet?Semantic proximity Read ↗

The μ-opioid receptor and treatment response to naltrexone.Semantic proximity Read ↗

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.Semantic proximity Read ↗

Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.Semantic proximity Read ↗

Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.